Latest News

  • Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results Read More
  • Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder Read More
  • Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team